Genentech/Wellcome TPA litigation
Executive Summary
On Oct. 31, the British Court of Appeals rejected Genentech's broad patent claims covering its clot dissolver, TPA. The decision upholds an earlier lower court ruling. Genentech said it does not believe the decision will affect Genentech's TPA patent position in the U.S. Genentech has been in litigation with Wellcome since Genentech was granted a U.K. patent and a subsequent U.S. recombinant patent. Genentech has a patent infringement suit against Wellcome pending in Delaware Federal Court ("The Pink Sheet" Aug. 29, T&G-8).